NCT00539734View on ClinicalTrials.gov

Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

February 28, 2009

Conditions
Age-related Macular Degeneration
Interventions
DRUG

ranibizumab

A single dose of 0.5 mg ranibizumab injected intravitreally.

Trial Locations (1)

90110

Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai

All Listed Sponsors
lead

Prince of Songkla University

OTHER

NCT00539734 - Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter